Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Nitrendipine
- Accession Number
- DB01054 (APRD00421)
- Type
- Small Molecule
- Groups
- Approved
- Description
A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive. [PubChem]
- Structure
Structure for DB01054 (Nitrendipine)
- Synonyms
- 1,4-dihydro-2,6-Dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid ethyl methyl ester
- BAY e 5009
- Bayotensin
- Baypress
- Bylotensin
- Deiten
- Nidrel
- Nitrendipino
- Nitrendipinum
- International/Other Brands
- Bayotensin / Baypress / Deiten / Nidrel / Nitrepin / Nitrezic
- Categories
- ACE Inhibitors and Calcium Channel Blockers
- Agents Acting on the Renin-Angiotensin System
- Antihypertensive Agents
- Calcium Channel Blockers
- Cardiovascular Agents
- Cardiovascular System
- Combined Inhibitors of CYP3A4 and P-glycoprotein
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Substrates
- Dihydropyridines
- Hypotensive Agents
- Membrane Transport Modulators
- P-glycoprotein/ABCB1 Inhibitors
- Pyridines
- Vasodilator Agents
- UNII
- 9B627AW319
- CAS number
- 39562-70-4
- Weight
- Average: 360.3612
Monoisotopic: 360.132136382 - Chemical Formula
- C18H20N2O6
- InChI Key
- PVHUJELLJLJGLN-UHFFFAOYSA-N
- InChI
- InChI=1S/C18H20N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9,16,19H,5H2,1-4H3
- IUPAC Name
- 3-ethyl 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
- SMILES
- CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
Pharmacology
- Indication
For the treatment of mild to moderate hypertension
- Structured Indications
- Not Available
- Pharmacodynamics
Nitrendipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Nitrendipine is similar to other peripheral vasodilators. Nitrendipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
- Mechanism of action
By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Nitrendipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Target Actions Organism AVoltage-dependent L-type calcium channel subunit alpha-1C inhibitorHuman AVoltage-dependent calcium channel subunit alpha-2/delta-1 inhibitorHuman AVoltage-dependent L-type calcium channel subunit beta-2 inhibitorHuman AVoltage-dependent calcium channel gamma-1 subunit inhibitorHuman AVoltage-dependent L-type calcium channel subunit alpha-1D inhibitorHuman AVoltage-dependent L-type calcium channel subunit alpha-1S inhibitorHuman UVoltage-dependent calcium channel subunit alpha-2/delta-2 inhibitorHuman UVoltage-dependent T-type calcium channel subunit alpha-1H inhibitorHuman - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
> 99%
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Nitrendipine Action Pathway Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 2-HYDROXY-1,4-NAPHTHOQUINONE The risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Nitrendipine. Experimental 2-mercaptobenzothiazole The risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Nitrendipine. Vet Approved 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Nitrendipine. Experimental Acebutolol The serum concentration of Acebutolol can be increased when it is combined with Nitrendipine. Approved Acetaminophen The serum concentration of Acetaminophen can be increased when it is combined with Nitrendipine. Approved Acetylsalicylic acid The serum concentration of Acetylsalicylic acid can be increased when it is combined with Nitrendipine. Approved, Vet Approved Afatinib The serum concentration of Afatinib can be increased when it is combined with Nitrendipine. Approved Aldesleukin The risk or severity of adverse effects can be increased when Nitrendipine is combined with Aldesleukin. Approved Aldosterone The serum concentration of Aldosterone can be increased when it is combined with Nitrendipine. Experimental Alfuzosin Alfuzosin may increase the hypotensive activities of Nitrendipine. Approved, Investigational Aliskiren Nitrendipine may increase the hypotensive activities of Aliskiren. Approved, Investigational Alitretinoin The serum concentration of Alitretinoin can be increased when it is combined with Nitrendipine. Approved, Investigational Alprenolol Alprenolol may increase the hypotensive activities of Nitrendipine. Approved, Withdrawn Ambrisentan The serum concentration of Ambrisentan can be increased when it is combined with Nitrendipine. Approved, Investigational Amifostine Nitrendipine may increase the hypotensive activities of Amifostine. Approved, Investigational Amiloride The risk or severity of adverse effects can be increased when Nitrendipine is combined with Amiloride. Approved Amiodarone The metabolism of Nitrendipine can be decreased when combined with Amiodarone. Approved, Investigational Amitriptyline The serum concentration of Amitriptyline can be increased when it is combined with Nitrendipine. Approved Amlodipine Amlodipine may increase the hypotensive activities of Nitrendipine. Approved Amobarbital The metabolism of Nitrendipine can be increased when combined with Amobarbital. Approved, Illicit Amorolfine The risk or severity of adverse effects can be increased when Amorolfine is combined with Nitrendipine. Approved Amphotericin B The risk or severity of adverse effects can be increased when Amphotericin B is combined with Nitrendipine. Approved, Investigational Amyl Nitrite The risk or severity of adverse effects can be increased when Nitrendipine is combined with Amyl Nitrite. Approved Anidulafungin The risk or severity of adverse effects can be increased when Anidulafungin is combined with Nitrendipine. Approved, Investigational Apixaban The serum concentration of Apixaban can be increased when it is combined with Nitrendipine. Approved Apomorphine The risk or severity of adverse effects can be increased when Apomorphine is combined with Nitrendipine. Approved, Investigational Apraclonidine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Apraclonidine. Approved Aprepitant The serum concentration of Nitrendipine can be increased when it is combined with Aprepitant. Approved, Investigational Aripiprazole Aripiprazole may increase the hypotensive activities of Nitrendipine. Approved, Investigational Arotinolol The risk or severity of adverse effects can be increased when Arotinolol is combined with Nitrendipine. Approved Arsenic trioxide The serum concentration of Arsenic trioxide can be increased when it is combined with Nitrendipine. Approved, Investigational Artemether The risk or severity of adverse effects can be increased when Artemether is combined with Nitrendipine. Approved Atazanavir The metabolism of Nitrendipine can be decreased when combined with Atazanavir. Approved, Investigational Atenolol The serum concentration of Atenolol can be increased when it is combined with Nitrendipine. Approved Atomoxetine The metabolism of Nitrendipine can be decreased when combined with Atomoxetine. Approved Atorvastatin The risk or severity of adverse effects can be increased when Nitrendipine is combined with Atorvastatin. Approved Atosiban The risk or severity of adverse effects can be increased when Nitrendipine is combined with Atosiban. Approved Atracurium besylate Nitrendipine may increase the neuromuscular blocking activities of Atracurium besylate. Approved Axitinib The serum concentration of Axitinib can be increased when it is combined with Nitrendipine. Approved, Investigational Azilsartan medoxomil The risk or severity of adverse effects can be increased when Nitrendipine is combined with Azilsartan medoxomil. Approved Bafilomycin A1 The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Nitrendipine. Experimental Barbexaclone Barbexaclone may increase the hypotensive activities of Nitrendipine. Experimental Barbital The metabolism of Nitrendipine can be increased when combined with Barbital. Illicit Barnidipine The risk or severity of adverse effects can be increased when Barnidipine is combined with Nitrendipine. Approved Belinostat The serum concentration of Belinostat can be increased when it is combined with Nitrendipine. Approved, Investigational Benazepril Benazepril may increase the hypotensive activities of Nitrendipine. Approved, Investigational Bendroflumethiazide Bendroflumethiazide may increase the hypotensive activities of Nitrendipine. Approved Benmoxin Benmoxin may increase the hypotensive activities of Nitrendipine. Withdrawn Benzoic Acid The risk or severity of adverse effects can be increased when Benzoic Acid is combined with Nitrendipine. Approved Bepridil Nitrendipine may increase the hypotensive activities of Bepridil. Approved, Withdrawn Betamethasone The serum concentration of Betamethasone can be increased when it is combined with Nitrendipine. Approved, Vet Approved Betaxolol Betaxolol may increase the hypotensive activities of Nitrendipine. Approved Bethanidine Bethanidine may increase the hypotensive activities of Nitrendipine. Approved Bietaserpine Bietaserpine may increase the hypotensive activities of Nitrendipine. Experimental Bifonazole The risk or severity of adverse effects can be increased when Bifonazole is combined with Nitrendipine. Approved Bimatoprost Bimatoprost may increase the hypotensive activities of Nitrendipine. Approved, Investigational Bisoprolol Bisoprolol may increase the hypotensive activities of Nitrendipine. Approved Boceprevir The metabolism of Nitrendipine can be decreased when combined with Boceprevir. Withdrawn Bortezomib The metabolism of Nitrendipine can be decreased when combined with Bortezomib. Approved, Investigational Bosentan The serum concentration of Nitrendipine can be decreased when it is combined with Bosentan. Approved, Investigational Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Nitrendipine. Approved BQ-123 Nitrendipine may increase the hypotensive activities of BQ-123. Investigational Brefeldin A The risk or severity of adverse effects can be increased when 1,6,7,8,9,11A,12,13,14,14A-DECAHYDRO-1,13-DIHYDROXY-6-METHYL-4H-CYCLOPENT[F]OXACYCLOTRIDECIN-4-ONE is combined with Nitrendipine. Experimental Brentuximab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Nitrendipine. Approved Bretylium Nitrendipine may increase the hypotensive activities of Bretylium. Approved Brimonidine Brimonidine may increase the antihypertensive activities of Nitrendipine. Approved Brofaromine Brofaromine may increase the hypotensive activities of Nitrendipine. Experimental Bromocriptine The serum concentration of Bromocriptine can be increased when it is combined with Nitrendipine. Approved, Investigational Bucindolol Bucindolol may increase the hypotensive activities of Nitrendipine. Investigational Bumetanide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Bumetanide. Approved Bunazosin Bunazosin may increase the hypotensive activities of Nitrendipine. Investigational Bupivacaine The risk or severity of adverse effects can be increased when Bupivacaine is combined with Nitrendipine. Approved, Investigational Bupranolol Nitrendipine may increase the hypotensive activities of Bupranolol. Approved Butenafine The risk or severity of adverse effects can be increased when Butenafine is combined with Nitrendipine. Approved Butoconazole The risk or severity of adverse effects can be increased when Butoconazole is combined with Nitrendipine. Approved Cabazitaxel The serum concentration of Cabazitaxel can be increased when it is combined with Nitrendipine. Approved Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Nitrendipine. Approved Cadralazine Cadralazine may increase the hypotensive activities of Nitrendipine. Experimental Cafedrine Nitrendipine may increase the hypotensive activities of Cafedrine. Investigational Caffeine The serum concentration of Caffeine can be increased when it is combined with Nitrendipine. Approved Calcium The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium. Nutraceutical Calcium Acetate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Acetate. Approved Calcium Carbonate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Carbonate. Approved Calcium Citrate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Citrate. Approved Calcium glubionate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium glubionate. Approved Calcium Gluceptate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Gluceptate. Approved Calcium gluconate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium gluconate. Approved, Vet Approved Calcium lactate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium lactate. Approved, Experimental, Vet Approved Calcium lactate gluconate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium lactate gluconate. Experimental Calcium laevulate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium laevulate. Experimental Calcium pangamate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium pangamate. Experimental Calcium Phosphate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Phosphate. Approved Camptothecin The serum concentration of Camptothecin can be increased when it is combined with Nitrendipine. Experimental Canagliflozin The serum concentration of Canagliflozin can be increased when it is combined with Nitrendipine. Approved Candesartan Candesartan may increase the hypotensive activities of Nitrendipine. Approved Candicidin The risk or severity of adverse effects can be increased when Candicidin is combined with Nitrendipine. Withdrawn Candoxatril Candoxatril may increase the hypotensive activities of Nitrendipine. Experimental Capric acid The risk or severity of adverse effects can be increased when Capric acid is combined with Nitrendipine. Experimental Captopril Nitrendipine may increase the hypotensive activities of Captopril. Approved Carbamazepine The metabolism of Nitrendipine can be increased when combined with Carbamazepine. Approved, Investigational Carbetocin The risk or severity of adverse effects can be increased when Carbetocin is combined with Nitrendipine. Approved Carbomycin The metabolism of Nitrendipine can be decreased when combined with Carbomycin. Vet Approved Carfilzomib The serum concentration of Carfilzomib can be increased when it is combined with Nitrendipine. Approved Caroxazone Caroxazone may increase the hypotensive activities of Nitrendipine. Withdrawn Carteolol Carteolol may increase the hypotensive activities of Nitrendipine. Approved Carvedilol Nitrendipine may increase the hypotensive activities of Carvedilol. Approved, Investigational Casein The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Casein. Approved Caspofungin The risk or severity of adverse effects can be increased when Caspofungin is combined with Nitrendipine. Approved Celiprolol Nitrendipine may increase the hypotensive activities of Celiprolol. Approved, Investigational Ceritinib The serum concentration of Nitrendipine can be increased when it is combined with Ceritinib. Approved Cerivastatin The serum concentration of Cerivastatin can be increased when it is combined with Nitrendipine. Withdrawn Cerulenin The risk or severity of adverse effects can be increased when Cerulenin is combined with Nitrendipine. Approved Chlorothiazide Chlorothiazide may increase the hypotensive activities of Nitrendipine. Approved, Vet Approved Chloroxine The risk or severity of adverse effects can be increased when Chloroxine is combined with Nitrendipine. Approved Chlorpromazine The serum concentration of Chlorpromazine can be increased when it is combined with Nitrendipine. Approved, Vet Approved Chlorthalidone Chlorthalidone may increase the hypotensive activities of Nitrendipine. Approved Cicletanine Nitrendipine may increase the hypotensive activities of Cicletanine. Investigational Ciclopirox The risk or severity of adverse effects can be increased when Ciclopirox is combined with Nitrendipine. Approved, Investigational Cilazapril Nitrendipine may increase the hypotensive activities of Cilazapril. Approved Cilnidipine The risk or severity of adverse effects can be increased when Cilnidipine is combined with Nitrendipine. Approved Cimetidine The serum concentration of Nitrendipine can be increased when it is combined with Cimetidine. Approved Ciprofloxacin The serum concentration of Ciprofloxacin can be increased when it is combined with Nitrendipine. Approved, Investigational Cisplatin The serum concentration of Cisplatin can be increased when it is combined with Nitrendipine. Approved Citalopram The serum concentration of Citalopram can be increased when it is combined with Nitrendipine. Approved Clarithromycin The metabolism of Nitrendipine can be decreased when combined with Clarithromycin. Approved Clemastine The metabolism of Nitrendipine can be decreased when combined with Clemastine. Approved Clevidipine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Clevidipine. Approved Clobazam The serum concentration of Clobazam can be increased when it is combined with Nitrendipine. Approved, Illicit Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Nitrendipine. Approved, Investigational Clomifene The serum concentration of Clomifene can be increased when it is combined with Nitrendipine. Approved, Investigational Clomipramine The risk or severity of adverse effects can be increased when Clomipramine is combined with Nitrendipine. Approved, Vet Approved Clonidine The serum concentration of Clonidine can be increased when it is combined with Nitrendipine. Approved Clopidogrel The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nitrendipine. Approved, Nutraceutical Cloranolol Nitrendipine may increase the hypotensive activities of Cloranolol. Experimental Clotrimazole The risk or severity of adverse effects can be increased when Clotrimazole is combined with Nitrendipine. Approved, Vet Approved Clozapine The serum concentration of Clozapine can be increased when it is combined with Nitrendipine. Approved Cobicistat The metabolism of Nitrendipine can be decreased when combined with Cobicistat. Approved Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Nitrendipine. Approved Colchicine The serum concentration of Colchicine can be increased when it is combined with Nitrendipine. Approved Conivaptan The serum concentration of Nitrendipine can be increased when it is combined with Conivaptan. Approved, Investigational Conjugated estrogens The serum concentration of Conjugated estrogens can be increased when it is combined with Nitrendipine. Approved Copanlisib The serum concentration of Copanlisib can be increased when it is combined with Nitrendipine. Approved Cordycepin The risk or severity of adverse effects can be increased when Cordycepin is combined with Nitrendipine. Investigational Crizotinib The metabolism of Nitrendipine can be decreased when combined with Crizotinib. Approved Cryptenamine Cryptenamine may increase the hypotensive activities of Nitrendipine. Approved Cyclopenthiazide Nitrendipine may increase the hypotensive activities of Cyclopenthiazide. Experimental Cyclosporine The risk or severity of adverse effects can be increased when Cyclosporine is combined with Nitrendipine. Approved, Investigational, Vet Approved Cyclothiazide Cyclothiazide may increase the hypotensive activities of Nitrendipine. Approved Dabigatran etexilate The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nitrendipine. Approved Dabrafenib The serum concentration of Nitrendipine can be decreased when it is combined with Dabrafenib. Approved Dactinomycin The serum concentration of Dactinomycin can be increased when it is combined with Nitrendipine. Approved Dapagliflozin The serum concentration of Dapagliflozin can be increased when it is combined with Nitrendipine. Approved Dapoxetine Dapoxetine may increase the orthostatic hypotensive activities of Nitrendipine. Investigational Darunavir The metabolism of Nitrendipine can be decreased when combined with Darunavir. Approved Dasatinib The serum concentration of Nitrendipine can be increased when it is combined with Dasatinib. Approved, Investigational Daunorubicin The serum concentration of Daunorubicin can be increased when it is combined with Nitrendipine. Approved Debrisoquin The serum concentration of Debrisoquin can be increased when it is combined with Nitrendipine. Approved Deferasirox The serum concentration of Nitrendipine can be decreased when it is combined with Deferasirox. Approved, Investigational Delapril Nitrendipine may increase the hypotensive activities of Delapril. Experimental Delavirdine The metabolism of Nitrendipine can be decreased when combined with Delavirdine. Approved Deserpidine Nitrendipine may increase the hypotensive activities of Deserpidine. Approved Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Nitrendipine. Approved Dexamethasone The serum concentration of Dexamethasone can be increased when it is combined with Nitrendipine. Approved, Investigational, Vet Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Dexmedetomidine. Approved, Vet Approved Diazepam The serum concentration of Diazepam can be increased when it is combined with Nitrendipine. Approved, Illicit, Vet Approved Diazoxide Diazoxide may increase the hypotensive activities of Nitrendipine. Approved Dichlorophene The risk or severity of adverse effects can be increased when Dichlorophene is combined with Nitrendipine. Vet Approved Diclofenamide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Diclofenamide. Approved diethylnorspermine Nitrendipine may increase the hypotensive activities of diethylnorspermine. Investigational Diethylstilbestrol The serum concentration of Diethylstilbestrol can be increased when it is combined with Nitrendipine. Approved Digitoxin The serum concentration of Digitoxin can be increased when it is combined with Nitrendipine. Approved Digoxin The serum concentration of Digoxin can be increased when it is combined with Nitrendipine. Approved Dihydralazine Dihydralazine may increase the hypotensive activities of Nitrendipine. Investigational Dihydroergocornine The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Nitrendipine. Approved Dihydroergocristine The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Nitrendipine. Experimental Dihydroergocryptine The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Nitrendipine. Experimental Dihydroergotamine The metabolism of Nitrendipine can be decreased when combined with Dihydroergotamine. Approved Dihydrotestosterone The serum concentration of Dihydrotestosterone can be increased when it is combined with Nitrendipine. Illicit Diltiazem The metabolism of Nitrendipine can be decreased when combined with Diltiazem. Approved Dinutuximab The risk or severity of adverse effects can be increased when Nitrendipine is combined with Dinutuximab. Approved Dipyridamole The serum concentration of Dipyridamole can be increased when it is combined with Nitrendipine. Approved Docetaxel The serum concentration of Docetaxel can be increased when it is combined with Nitrendipine. Approved, Investigational Domperidone The serum concentration of Domperidone can be increased when it is combined with Nitrendipine. Approved, Investigational, Vet Approved Dorzolamide Dorzolamide may increase the hypotensive activities of Nitrendipine. Approved Doxazosin Doxazosin may increase the hypotensive activities of Nitrendipine. Approved Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Nitrendipine. Approved, Investigational Doxycycline The metabolism of Nitrendipine can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Dronedarone The metabolism of Nitrendipine can be decreased when combined with Dronedarone. Approved Duloxetine Nitrendipine may increase the orthostatic hypotensive activities of Duloxetine. Approved Econazole The risk or severity of adverse effects can be increased when Econazole is combined with Nitrendipine. Approved Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Nitrendipine. Approved Efavirenz The serum concentration of Nitrendipine can be decreased when it is combined with Efavirenz. Approved, Investigational Efinaconazole The risk or severity of adverse effects can be increased when Efinaconazole is combined with Nitrendipine. Approved Efonidipine Nitrendipine may increase the hypotensive activities of Efonidipine. Approved Elbasvir The serum concentration of Elbasvir can be increased when it is combined with Nitrendipine. Approved Eletriptan The serum concentration of Eletriptan can be increased when it is combined with Nitrendipine. Approved, Investigational Empagliflozin The risk or severity of adverse effects can be increased when Nitrendipine is combined with Empagliflozin. Approved Enalapril Enalapril may increase the hypotensive activities of Nitrendipine. Approved, Vet Approved Enalaprilat Nitrendipine may increase the hypotensive activities of Enalaprilat. Approved Enasidenib The serum concentration of Enasidenib can be increased when it is combined with Nitrendipine. Approved Endralazine Endralazine may increase the hypotensive activities of Nitrendipine. Experimental Enzalutamide The serum concentration of Nitrendipine can be decreased when it is combined with Enzalutamide. Approved Epanolol Nitrendipine may increase the hypotensive activities of Epanolol. Experimental Epinastine The serum concentration of Epinastine can be increased when it is combined with Nitrendipine. Approved, Investigational Eplerenone The risk or severity of adverse effects can be increased when Nitrendipine is combined with Eplerenone. Approved Epoprostenol Nitrendipine may increase the hypotensive activities of Epoprostenol. Approved Eprosartan Eprosartan may increase the hypotensive activities of Nitrendipine. Approved Ergonovine The risk or severity of adverse effects can be increased when Ergonovine is combined with Nitrendipine. Approved Ergotamine The risk or severity of adverse effects can be increased when Ergotamine is combined with Nitrendipine. Approved Erlotinib The serum concentration of Erlotinib can be increased when it is combined with Nitrendipine. Approved, Investigational Erythromycin The metabolism of Nitrendipine can be decreased when combined with Erythromycin. Approved, Vet Approved Esmolol The risk or severity of adverse effects can be increased when Nitrendipine is combined with Esmolol. Approved Estradiol The serum concentration of Estradiol can be increased when it is combined with Nitrendipine. Approved, Investigational, Vet Approved Estriol The serum concentration of Estriol can be increased when it is combined with Nitrendipine. Approved, Vet Approved Estrone The serum concentration of Estrone can be increased when it is combined with Nitrendipine. Approved Etacrynic acid The risk or severity of adverse effects can be increased when Nitrendipine is combined with Etacrynic acid. Approved Ethinyl Estradiol The serum concentration of Ethinyl Estradiol can be increased when it is combined with Nitrendipine. Approved Etoposide The serum concentration of Etoposide can be increased when it is combined with Nitrendipine. Approved Everolimus The serum concentration of Everolimus can be increased when it is combined with Nitrendipine. Approved Ezetimibe The serum concentration of Ezetimibe can be increased when it is combined with Nitrendipine. Approved Felodipine Felodipine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Fenoldopam Fenoldopam may increase the hypotensive activities of Nitrendipine. Approved Fenticonazole The risk or severity of adverse effects can be increased when Fenticonazole is combined with Nitrendipine. Experimental Ferulic acid Nitrendipine may increase the hypotensive activities of Ferulic acid. Experimental Fesoterodine The serum concentration of Fesoterodine can be increased when it is combined with Nitrendipine. Approved Fexofenadine The serum concentration of Fexofenadine can be increased when it is combined with Nitrendipine. Approved Fidaxomicin The serum concentration of Fidaxomicin can be increased when it is combined with Nitrendipine. Approved Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Nitrendipine. Approved Fluconazole The serum concentration of Nitrendipine can be increased when it is combined with Fluconazole. Approved Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Nitrendipine. Approved Fluticasone furoate The serum concentration of Fluticasone furoate can be increased when it is combined with Nitrendipine. Approved Flutrimazole The risk or severity of adverse effects can be increased when Flutrimazole is combined with Nitrendipine. Experimental Fluvastatin The serum concentration of Fluvastatin can be increased when it is combined with Nitrendipine. Approved Fluvoxamine The metabolism of Nitrendipine can be decreased when combined with Fluvoxamine. Approved, Investigational Fosamprenavir The metabolism of Nitrendipine can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Nitrendipine can be increased when it is combined with Fosaprepitant. Approved Fosinopril Fosinopril may increase the hypotensive activities of Nitrendipine. Approved Fosphenytoin The serum concentration of Fosphenytoin can be increased when it is combined with Nitrendipine. Approved Furazolidone Furazolidone may increase the hypotensive activities of Nitrendipine. Approved, Vet Approved Furosemide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Furosemide. Approved, Vet Approved Fusidic Acid The serum concentration of Nitrendipine can be increased when it is combined with Fusidic Acid. Approved Gefitinib The serum concentration of Gefitinib can be increased when it is combined with Nitrendipine. Approved, Investigational Gemcitabine The serum concentration of Gemcitabine can be increased when it is combined with Nitrendipine. Approved Glecaprevir The serum concentration of Glecaprevir can be increased when it is combined with Nitrendipine. Approved Glyphosate The risk or severity of adverse effects can be increased when Glyphosate is combined with Nitrendipine. Experimental Grazoprevir The serum concentration of Grazoprevir can be increased when it is combined with Nitrendipine. Approved Grepafloxacin The serum concentration of Grepafloxacin can be increased when it is combined with Nitrendipine. Withdrawn Griseofulvin The risk or severity of adverse effects can be increased when Griseofulvin is combined with Nitrendipine. Approved, Vet Approved Guanabenz Guanabenz may increase the hypotensive activities of Nitrendipine. Approved Guanadrel Guanadrel may increase the hypotensive activities of Nitrendipine. Approved Guanazodine Nitrendipine may increase the hypotensive activities of Guanazodine. Experimental Guanethidine Guanethidine may increase the hypotensive activities of Nitrendipine. Approved Guanfacine Guanfacine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Guanoclor Nitrendipine may increase the hypotensive activities of Guanoclor. Experimental Guanoxabenz Nitrendipine may increase the hypotensive activities of Guanoxabenz. Experimental Guanoxan Nitrendipine may increase the hypotensive activities of Guanoxan. Experimental Hachimycin The risk or severity of adverse effects can be increased when Hachimycin is combined with Nitrendipine. Experimental Haloperidol The serum concentration of Haloperidol can be increased when it is combined with Nitrendipine. Approved Haloprogin The risk or severity of adverse effects can be increased when Haloprogin is combined with Nitrendipine. Approved, Withdrawn Halothane The risk or severity of adverse effects can be increased when Halothane is combined with Nitrendipine. Approved, Vet Approved Harmaline Harmaline may increase the hypotensive activities of Nitrendipine. Experimental Hexamethonium Nitrendipine may increase the hypotensive activities of Hexamethonium. Experimental Hexetidine The risk or severity of adverse effects can be increased when Hexetidine is combined with Nitrendipine. Approved Hexobarbital The metabolism of Nitrendipine can be increased when combined with Hexobarbital. Approved Hydracarbazine Hydracarbazine may increase the hypotensive activities of Nitrendipine. Experimental Hydralazine Hydralazine may increase the hypotensive activities of Nitrendipine. Approved Hydrochlorothiazide Hydrochlorothiazide may increase the hypotensive activities of Nitrendipine. Approved, Vet Approved Hydrocortisone The serum concentration of Hydrocortisone can be increased when it is combined with Nitrendipine. Approved, Vet Approved Hydroflumethiazide Hydroflumethiazide may increase the hypotensive activities of Nitrendipine. Approved Ibuprofen The serum concentration of Ibuprofen can be increased when it is combined with Nitrendipine. Approved Idelalisib The serum concentration of Nitrendipine can be increased when it is combined with Idelalisib. Approved Iloprost Iloprost may increase the hypotensive activities of Nitrendipine. Approved, Investigational Imatinib The metabolism of Nitrendipine can be decreased when combined with Imatinib. Approved Imidapril The risk or severity of adverse effects can be increased when Imidapril is combined with Nitrendipine. Investigational Imipramine The serum concentration of Imipramine can be increased when it is combined with Nitrendipine. Approved Indacaterol The serum concentration of Indacaterol can be increased when it is combined with Nitrendipine. Approved Indapamide Indapamide may increase the hypotensive activities of Nitrendipine. Approved Indenolol Nitrendipine may increase the hypotensive activities of Indenolol. Withdrawn Indinavir The metabolism of Nitrendipine can be decreased when combined with Indinavir. Approved Indomethacin The serum concentration of Indomethacin can be increased when it is combined with Nitrendipine. Approved, Investigational Indoramin Indoramin may increase the hypotensive activities of Nitrendipine. Withdrawn Inotuzumab ozogamicin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Nitrendipine. Approved Iproclozide Iproclozide may increase the hypotensive activities of Nitrendipine. Withdrawn Iproniazid Iproniazid may increase the hypotensive activities of Nitrendipine. Withdrawn Irbesartan Irbesartan may increase the hypotensive activities of Nitrendipine. Approved, Investigational Irinotecan The serum concentration of Irinotecan can be increased when it is combined with Nitrendipine. Approved, Investigational Isavuconazonium The metabolism of Nitrendipine can be decreased when combined with Isavuconazonium. Approved, Investigational Isocarboxazid Isocarboxazid may increase the hypotensive activities of Nitrendipine. Approved Isoconazole The risk or severity of adverse effects can be increased when Isoconazole is combined with Nitrendipine. Approved Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Nitrendipine. Approved, Vet Approved Isosorbide Dinitrate The risk or severity of adverse effects can be increased when Nitrendipine is combined with Isosorbide Dinitrate. Approved Isosorbide Mononitrate The risk or severity of adverse effects can be increased when Nitrendipine is combined with Isosorbide Mononitrate. Approved Isoxsuprine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Isoxsuprine. Approved, Withdrawn Isradipine The metabolism of Nitrendipine can be decreased when combined with Isradipine. Approved Itraconazole The metabolism of Nitrendipine can be decreased when combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Nitrendipine can be increased when it is combined with Ivacaftor. Approved Ivermectin The serum concentration of Ivermectin can be increased when it is combined with Nitrendipine. Approved, Vet Approved Josamycin The metabolism of Nitrendipine can be decreased when combined with Josamycin. Approved Ketanserin Ketanserin may increase the hypotensive activities of Nitrendipine. Investigational Ketazolam The serum concentration of Ketazolam can be increased when it is combined with Nitrendipine. Approved Ketoconazole The metabolism of Nitrendipine can be decreased when combined with Ketoconazole. Approved, Investigational Kitasamycin The metabolism of Nitrendipine can be decreased when combined with Kitasamycin. Experimental Labetalol Labetalol may increase the hypotensive activities of Nitrendipine. Approved Lacidipine Nitrendipine may increase the hypotensive activities of Lacidipine. Approved Lamivudine The serum concentration of Lamivudine can be increased when it is combined with Nitrendipine. Approved, Investigational Lamotrigine The serum concentration of Lamotrigine can be increased when it is combined with Nitrendipine. Approved, Investigational Lansoprazole The serum concentration of Lansoprazole can be increased when it is combined with Nitrendipine. Approved, Investigational Latanoprost Latanoprost may increase the hypotensive activities of Nitrendipine. Approved, Investigational Ledipasvir The serum concentration of Ledipasvir can be increased when it is combined with Nitrendipine. Approved Lenalidomide The serum concentration of Lenalidomide can be increased when it is combined with Nitrendipine. Approved Lenvatinib The serum concentration of Lenvatinib can be increased when it is combined with Nitrendipine. Approved Lercanidipine Lercanidipine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Levetiracetam The serum concentration of Levetiracetam can be increased when it is combined with Nitrendipine. Approved, Investigational Levobunolol The risk or severity of adverse effects can be increased when Nitrendipine is combined with Levobunolol. Approved Levobupivacaine The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nitrendipine. Approved Levodopa Nitrendipine may increase the orthostatic hypotensive activities of Levodopa. Approved Levofloxacin The serum concentration of Levofloxacin can be increased when it is combined with Nitrendipine. Approved, Investigational Levomilnacipran The serum concentration of Levomilnacipran can be increased when it is combined with Nitrendipine. Approved Levosimendan The risk or severity of adverse effects can be increased when Levosimendan is combined with Nitrendipine. Approved, Investigational Linagliptin The serum concentration of Linagliptin can be increased when it is combined with Nitrendipine. Approved Linsidomine Nitrendipine may increase the hypotensive activities of Linsidomine. Experimental Lisinopril Lisinopril may increase the hypotensive activities of Nitrendipine. Approved, Investigational Lisuride The risk or severity of adverse effects can be increased when Lisuride is combined with Nitrendipine. Approved Lofexidine Nitrendipine may increase the hypotensive activities of Lofexidine. Approved, Investigational Loperamide The serum concentration of Loperamide can be increased when it is combined with Nitrendipine. Approved Lopinavir The metabolism of Nitrendipine can be decreased when combined with Lopinavir. Approved Losartan The serum concentration of Losartan can be increased when it is combined with Nitrendipine. Approved Lovastatin The metabolism of Nitrendipine can be decreased when combined with Lovastatin. Approved, Investigational Luliconazole The serum concentration of Nitrendipine can be increased when it is combined with Luliconazole. Approved Lumacaftor The metabolism of Nitrendipine can be increased when combined with Lumacaftor. Approved Lysergic Acid Diethylamide The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Nitrendipine. Illicit, Withdrawn Macitentan Nitrendipine may increase the hypotensive activities of Macitentan. Approved Magnesium Hydroxide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium Hydroxide. Approved Magnesium oxide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium oxide. Approved Magnesium salicylate The risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium salicylate. Approved Magnesium Sulfate The risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium Sulfate. Approved, Vet Approved Manidipine Nitrendipine may increase the hypotensive activities of Manidipine. Approved Mannitol The serum concentration of Mannitol can be increased when it is combined with Nitrendipine. Approved, Investigational Mebanazine Mebanazine may increase the hypotensive activities of Nitrendipine. Withdrawn Mecamylamine Mecamylamine may increase the hypotensive activities of Nitrendipine. Approved Mepartricin The risk or severity of adverse effects can be increased when Mepartricin is combined with Nitrendipine. Experimental Metergoline The risk or severity of adverse effects can be increased when Metergoline is combined with Nitrendipine. Experimental Methazolamide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Methazolamide. Approved Methohexital The metabolism of Nitrendipine can be increased when combined with Methohexital. Approved Methoserpidine Nitrendipine may increase the hypotensive activities of Methoserpidine. Experimental Methotrexate The serum concentration of Methotrexate can be increased when it is combined with Nitrendipine. Approved Methyclothiazide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Methyclothiazide. Approved Methyldopa Methyldopa may increase the hypotensive activities of Nitrendipine. Approved Methylene blue Methylene blue may increase the hypotensive activities of Nitrendipine. Investigational Methylergometrine The risk or severity of adverse effects can be increased when Methylergometrine is combined with Nitrendipine. Approved Methylphenidate Methylphenidate may decrease the antihypertensive activities of Nitrendipine. Approved, Investigational Methylphenobarbital The metabolism of Nitrendipine can be increased when combined with Methylphenobarbital. Approved Methylprednisolone The serum concentration of Methylprednisolone can be increased when it is combined with Nitrendipine. Approved, Vet Approved Methysergide The risk or severity of adverse effects can be increased when Methysergide is combined with Nitrendipine. Approved Metipranolol Nitrendipine may increase the hypotensive activities of Metipranolol. Approved Metolazone Metolazone may increase the hypotensive activities of Nitrendipine. Approved Metoprolol The serum concentration of Metoprolol can be increased when it is combined with Nitrendipine. Approved, Investigational Metyrosine Nitrendipine may increase the hypotensive activities of Metyrosine. Approved Mevastatin The risk or severity of adverse effects can be increased when Mevastatin is combined with Nitrendipine. Experimental Mibefradil Nitrendipine may increase the hypotensive activities of Mibefradil. Withdrawn Micafungin The risk or severity of adverse effects can be increased when Micafungin is combined with Nitrendipine. Approved, Investigational Miconazole The risk or severity of adverse effects can be increased when Miconazole is combined with Nitrendipine. Approved, Investigational, Vet Approved Midazolam The serum concentration of Midazolam can be increased when it is combined with Nitrendipine. Approved, Illicit Mifepristone The serum concentration of Nitrendipine can be increased when it is combined with Mifepristone. Approved, Investigational Miltefosine The risk or severity of adverse effects can be increased when Miltefosine is combined with Nitrendipine. Approved Minaprine Minaprine may increase the hypotensive activities of Nitrendipine. Approved Minoxidil Minoxidil may increase the hypotensive activities of Nitrendipine. Approved Mirabegron The serum concentration of Mirabegron can be increased when it is combined with Nitrendipine. Approved Mirodenafil Mirodenafil may increase the antihypertensive activities of Nitrendipine. Investigational Mitotane The serum concentration of Nitrendipine can be decreased when it is combined with Mitotane. Approved Mitoxantrone The serum concentration of Mitoxantrone can be increased when it is combined with Nitrendipine. Approved, Investigational Mivacurium Nitrendipine may increase the neuromuscular blocking activities of Mivacurium. Approved Moclobemide Moclobemide may increase the hypotensive activities of Nitrendipine. Approved Moexipril Moexipril may increase the hypotensive activities of Nitrendipine. Approved Molsidomine Molsidomine may increase the hypotensive activities of Nitrendipine. Approved Monensin The risk or severity of adverse effects can be increased when Monensin is combined with Nitrendipine. Vet Approved Morphine The serum concentration of Morphine can be increased when it is combined with Nitrendipine. Approved, Investigational Moxonidine Moxonidine may increase the hypotensive activities of Nitrendipine. Approved Muzolimine Nitrendipine may increase the hypotensive activities of Muzolimine. Experimental Mycophenolate mofetil The serum concentration of Mycophenolate mofetil can be increased when it is combined with Nitrendipine. Approved, Investigational Myxothiazol The risk or severity of adverse effects can be increased when Myxothiazol is combined with Nitrendipine. Experimental Nabilone The risk or severity of adverse effects can be increased when Nabilone is combined with Nitrendipine. Approved, Investigational Nadolol The serum concentration of Nadolol can be increased when it is combined with Nitrendipine. Approved Nafcillin The metabolism of Nitrendipine can be increased when combined with Nafcillin. Approved Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Nitrendipine. Approved Naftopidil Nitrendipine may increase the hypotensive activities of Naftopidil. Investigational Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Nitrendipine. Approved Naloxone The serum concentration of Naloxone can be increased when it is combined with Nitrendipine. Approved, Vet Approved Natamycin The risk or severity of adverse effects can be increased when Natamycin is combined with Nitrendipine. Approved Nebivolol Nitrendipine may increase the hypotensive activities of Nebivolol. Approved, Investigational Nefazodone The metabolism of Nitrendipine can be decreased when combined with Nefazodone. Approved, Withdrawn Nelfinavir The metabolism of Nitrendipine can be decreased when combined with Nelfinavir. Approved Nesiritide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Nesiritide. Approved, Investigational Netupitant The serum concentration of Nitrendipine can be increased when it is combined with Netupitant. Approved Nevirapine The metabolism of Nitrendipine can be increased when combined with Nevirapine. Approved Nialamide Nialamide may increase the hypotensive activities of Nitrendipine. Withdrawn Nicardipine The serum concentration of Nicardipine can be increased when it is combined with Nitrendipine. Approved Nicergoline The risk or severity of adverse effects can be increased when Nicergoline is combined with Nitrendipine. Approved Nicorandil Nicorandil may increase the hypotensive activities of Nitrendipine. Approved Nifedipine The serum concentration of Nifedipine can be increased when it is combined with Nitrendipine. Approved Nifuratel The risk or severity of adverse effects can be increased when Nifuratel is combined with Nitrendipine. Experimental Niguldipine Nitrendipine may increase the hypotensive activities of Niguldipine. Experimental Nikkomycin Z The risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Nitrendipine. Investigational Nilotinib The metabolism of Nitrendipine can be decreased when combined with Nilotinib. Approved, Investigational Nilvadipine Nitrendipine may increase the hypotensive activities of Nilvadipine. Approved Nimodipine Nimodipine may increase the hypotensive activities of Nitrendipine. Approved Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Nitrendipine. Approved Nisoldipine Nisoldipine may increase the hypotensive activities of Nitrendipine. Approved Nitric Oxide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Nitric Oxide. Approved Nitroglycerin The risk or severity of adverse effects can be increased when Nitrendipine is combined with Nitroglycerin. Approved, Investigational Nitroprusside Nitrendipine may increase the hypotensive activities of Nitroprusside. Approved Nitroxoline The risk or severity of adverse effects can be increased when Nitroxoline is combined with Nitrendipine. Approved Nizatidine The serum concentration of Nizatidine can be increased when it is combined with Nitrendipine. Approved Nystatin The risk or severity of adverse effects can be increased when Nystatin is combined with Nitrendipine. Approved, Vet Approved Obinutuzumab Nitrendipine may increase the hypotensive activities of Obinutuzumab. Approved Octamoxin Octamoxin may increase the hypotensive activities of Nitrendipine. Withdrawn Odanacatib The serum concentration of Odanacatib can be increased when it is combined with Nitrendipine. Investigational Olanzapine The serum concentration of Olanzapine can be increased when it is combined with Nitrendipine. Approved, Investigational Olaparib The metabolism of Nitrendipine can be decreased when combined with Olaparib. Approved Oleandomycin The metabolism of Nitrendipine can be decreased when combined with Oleandomycin. Vet Approved Olmesartan Olmesartan may increase the hypotensive activities of Nitrendipine. Approved, Investigational Omapatrilat Omapatrilat may increase the hypotensive activities of Nitrendipine. Investigational Ombitasvir The serum concentration of Ombitasvir can be increased when it is combined with Nitrendipine. Approved Omoconazole The risk or severity of adverse effects can be increased when Omoconazole is combined with Nitrendipine. Experimental Osimertinib The serum concentration of Nitrendipine can be increased when it is combined with Osimertinib. Approved Oxiconazole The risk or severity of adverse effects can be increased when Oxiconazole is combined with Nitrendipine. Approved Oxprenolol Nitrendipine may increase the hypotensive activities of Oxprenolol. Approved Paclitaxel The serum concentration of Paclitaxel can be increased when it is combined with Nitrendipine. Approved, Vet Approved pafuramidine The risk or severity of adverse effects can be increased when pafuramidine is combined with Nitrendipine. Investigational Palbociclib The serum concentration of Nitrendipine can be increased when it is combined with Palbociclib. Approved Panobinostat The serum concentration of Panobinostat can be increased when it is combined with Nitrendipine. Approved, Investigational Papaverine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Papaverine. Approved Pargyline Pargyline may increase the hypotensive activities of Nitrendipine. Approved Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Nitrendipine. Approved Penbutolol Nitrendipine may increase the hypotensive activities of Penbutolol. Approved, Investigational Pentamidine The risk or severity of adverse effects can be increased when Pentamidine is combined with Nitrendipine. Approved Pentobarbital The metabolism of Nitrendipine can be increased when combined with Pentobarbital. Approved, Vet Approved Pentolinium Nitrendipine may increase the hypotensive activities of Pentolinium. Approved Pentoxifylline Pentoxifylline may increase the hypotensive activities of Nitrendipine. Approved, Investigational Pergolide The risk or severity of adverse effects can be increased when Pergolide is combined with Nitrendipine. Approved, Vet Approved, Withdrawn Perindopril Perindopril may increase the hypotensive activities of Nitrendipine. Approved Phenelzine Phenelzine may increase the hypotensive activities of Nitrendipine. Approved Pheniprazine Pheniprazine may increase the hypotensive activities of Nitrendipine. Withdrawn Phenobarbital The metabolism of Nitrendipine can be increased when combined with Phenobarbital. Approved Phenoxybenzamine Phenoxybenzamine may increase the hypotensive activities of Nitrendipine. Approved Phenoxypropazine Phenoxypropazine may increase the hypotensive activities of Nitrendipine. Withdrawn Phentolamine Phentolamine may increase the hypotensive activities of Nitrendipine. Approved Phenytoin The serum concentration of Phenytoin can be increased when it is combined with Nitrendipine. Approved, Vet Approved Pibrentasvir The serum concentration of Pibrentasvir can be increased when it is combined with Nitrendipine. Approved Pinacidil Pinacidil may increase the hypotensive activities of Nitrendipine. Withdrawn Pindolol Pindolol may increase the hypotensive activities of Nitrendipine. Approved Pipamperone The risk or severity of adverse effects can be increased when Nitrendipine is combined with Pipamperone. Approved Pirlindole Pirlindole may increase the hypotensive activities of Nitrendipine. Approved Pitavastatin The serum concentration of Pitavastatin can be increased when it is combined with Nitrendipine. Approved Pivhydrazine Pivhydrazine may increase the hypotensive activities of Nitrendipine. Withdrawn Polythiazide Nitrendipine may increase the hypotensive activities of Polythiazide. Approved Pomalidomide The serum concentration of Pomalidomide can be increased when it is combined with Nitrendipine. Approved Ponatinib The serum concentration of Ponatinib can be increased when it is combined with Nitrendipine. Approved Posaconazole The metabolism of Nitrendipine can be decreased when combined with Posaconazole. Approved, Investigational, Vet Approved Pramipexole The risk or severity of adverse effects can be increased when Nitrendipine is combined with Pramipexole. Approved, Investigational Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Nitrendipine. Approved Prazosin The serum concentration of Prazosin can be increased when it is combined with Nitrendipine. Approved Prednisolone The serum concentration of Prednisolone can be increased when it is combined with Nitrendipine. Approved, Vet Approved Prednisone The serum concentration of Prednisone can be increased when it is combined with Nitrendipine. Approved, Vet Approved Primidone The metabolism of Nitrendipine can be increased when combined with Primidone. Approved, Vet Approved Progesterone The serum concentration of Progesterone can be increased when it is combined with Nitrendipine. Approved, Vet Approved Propofol The risk or severity of adverse effects can be increased when Nitrendipine is combined with Propofol. Approved, Investigational, Vet Approved Propranolol The serum concentration of Propranolol can be increased when it is combined with Nitrendipine. Approved, Investigational Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Nitrendipine. Approved Pyrrolnitrin The risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Nitrendipine. Experimental Quetiapine The serum concentration of Quetiapine can be increased when it is combined with Nitrendipine. Approved Quinapril Quinapril may increase the hypotensive activities of Nitrendipine. Approved, Investigational Quinidine The serum concentration of Quinidine can be increased when it is combined with Nitrendipine. Approved Quinine Quinine may increase the hypotensive activities of Nitrendipine. Approved Radicicol The risk or severity of adverse effects can be increased when Radicicol is combined with Nitrendipine. Experimental Ramipril Ramipril may increase the hypotensive activities of Nitrendipine. Approved Ranitidine The serum concentration of Ranitidine can be increased when it is combined with Nitrendipine. Approved Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Nitrendipine. Approved, Investigational Rapacuronium Nitrendipine may increase the neuromuscular blocking activities of Rapacuronium. Withdrawn Rasagiline Rasagiline may increase the hypotensive activities of Nitrendipine. Approved Remifentanil The risk or severity of adverse effects can be increased when Nitrendipine is combined with Remifentanil. Approved Remikiren Remikiren may increase the hypotensive activities of Nitrendipine. Approved Rescinnamine Nitrendipine may increase the hypotensive activities of Rescinnamine. Approved Reserpine The serum concentration of Reserpine can be increased when it is combined with Nitrendipine. Approved Rifabutin The metabolism of Nitrendipine can be increased when combined with Rifabutin. Approved Rifampicin The metabolism of Nitrendipine can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Nitrendipine can be increased when combined with Rifapentine. Approved Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Nitrendipine. Approved, Investigational Rilmenidine Rilmenidine may increase the hypotensive activities of Nitrendipine. Investigational Riociguat Nitrendipine may increase the hypotensive activities of Riociguat. Approved Risperidone Nitrendipine may increase the hypotensive activities of Risperidone. Approved, Investigational Ritonavir The metabolism of Nitrendipine can be decreased when combined with Ritonavir. Approved, Investigational Rituximab Nitrendipine may increase the hypotensive activities of Rituximab. Approved Rivaroxaban The serum concentration of Rivaroxaban can be increased when it is combined with Nitrendipine. Approved Romidepsin The serum concentration of Romidepsin can be increased when it is combined with Nitrendipine. Approved, Investigational Ropinirole The risk or severity of adverse effects can be increased when Nitrendipine is combined with Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Ropivacaine. Approved Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Nitrendipine. Approved Rotigotine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Rotigotine. Approved Sacubitril The risk or severity of adverse effects can be increased when Nitrendipine is combined with Sacubitril. Approved Safrazine Safrazine may increase the hypotensive activities of Nitrendipine. Withdrawn Salicylhydroxamic Acid The risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Nitrendipine. Experimental Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Nitrendipine. Approved, Vet Approved Saprisartan Nitrendipine may increase the hypotensive activities of Saprisartan. Experimental Saquinavir The metabolism of Nitrendipine can be decreased when combined with Saquinavir. Approved, Investigational Secobarbital The metabolism of Nitrendipine can be increased when combined with Secobarbital. Approved, Vet Approved Selegiline Selegiline may increase the hypotensive activities of Nitrendipine. Approved, Investigational, Vet Approved Selexipag The serum concentration of Selexipag can be increased when it is combined with Nitrendipine. Approved Sertaconazole The risk or severity of adverse effects can be increased when Sertaconazole is combined with Nitrendipine. Approved Sevoflurane The risk or severity of adverse effects can be increased when Nitrendipine is combined with Sevoflurane. Approved, Vet Approved Sildenafil Sildenafil may increase the antihypertensive activities of Nitrendipine. Approved, Investigational Silodosin The serum concentration of Silodosin can be increased when it is combined with Nitrendipine. Approved Siltuximab The serum concentration of Nitrendipine can be decreased when it is combined with Siltuximab. Approved Simeprevir The serum concentration of Nitrendipine can be increased when it is combined with Simeprevir. Approved Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Nitrendipine. Approved Sinefungin The risk or severity of adverse effects can be increased when Sinefungin is combined with Nitrendipine. Experimental Sirolimus The risk or severity of adverse effects can be increased when Sirolimus is combined with Nitrendipine. Approved, Investigational Sitagliptin The serum concentration of Sitagliptin can be increased when it is combined with Nitrendipine. Approved, Investigational Sitaxentan Nitrendipine may increase the hypotensive activities of Sitaxentan. Approved, Investigational, Withdrawn Sodium Nitrite The risk or severity of adverse effects can be increased when Nitrendipine is combined with Sodium Nitrite. Approved Sofosbuvir The serum concentration of Sofosbuvir can be increased when it is combined with Nitrendipine. Approved Solithromycin The metabolism of Nitrendipine can be decreased when combined with Solithromycin. Investigational Sorafenib The serum concentration of Sorafenib can be increased when it is combined with Nitrendipine. Approved, Investigational Sotalol The risk or severity of adverse effects can be increased when Nitrendipine is combined with Sotalol. Approved Sparfloxacin The serum concentration of Sparfloxacin can be increased when it is combined with Nitrendipine. Approved Sphingosine The serum concentration of Sphingosine can be increased when it is combined with Nitrendipine. Experimental Spirapril Nitrendipine may increase the hypotensive activities of Spirapril. Approved Spironolactone The risk or severity of adverse effects can be increased when Nitrendipine is combined with Spironolactone. Approved St. John's Wort The serum concentration of Nitrendipine can be decreased when it is combined with St. John's Wort. Nutraceutical Stiripentol The serum concentration of Nitrendipine can be increased when it is combined with Stiripentol. Approved Streptokinase The risk or severity of adverse effects can be increased when Nitrendipine is combined with Streptokinase. Approved Sufentanil The risk or severity of adverse effects can be increased when Nitrendipine is combined with Sufentanil. Approved, Investigational Sulconazole The risk or severity of adverse effects can be increased when Sulconazole is combined with Nitrendipine. Approved Sulfisoxazole The metabolism of Nitrendipine can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Nitrendipine. Approved, Investigational Tadalafil Tadalafil may increase the antihypertensive activities of Nitrendipine. Approved, Investigational Talinolol Nitrendipine may increase the hypotensive activities of Talinolol. Investigational Tamoxifen The serum concentration of Tamoxifen can be increased when it is combined with Nitrendipine. Approved Tamsulosin Tamsulosin may increase the hypotensive activities of Nitrendipine. Approved, Investigational Taurocholic Acid The serum concentration of Taurocholic Acid can be increased when it is combined with Nitrendipine. Experimental Tavaborole The risk or severity of adverse effects can be increased when Tavaborole is combined with Nitrendipine. Approved Technetium Tc-99m sestamibi The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Nitrendipine. Approved Telaprevir The metabolism of Nitrendipine can be decreased when combined with Telaprevir. Withdrawn Telithromycin The metabolism of Nitrendipine can be decreased when combined with Telithromycin. Approved Telmisartan Telmisartan may increase the hypotensive activities of Nitrendipine. Approved, Investigational Temocapril Nitrendipine may increase the hypotensive activities of Temocapril. Experimental, Investigational Temsirolimus The serum concentration of Temsirolimus can be increased when it is combined with Nitrendipine. Approved Terazosin Terazosin may increase the hypotensive activities of Nitrendipine. Approved Terbinafine The risk or severity of adverse effects can be increased when Terbinafine is combined with Nitrendipine. Approved, Investigational, Vet Approved Terconazole The risk or severity of adverse effects can be increased when Terconazole is combined with Nitrendipine. Approved Terguride The risk or severity of adverse effects can be increased when Terguride is combined with Nitrendipine. Experimental Terlipressin Nitrendipine may increase the hypotensive activities of Terlipressin. Approved, Investigational Tetrahydropalmatine Nitrendipine may increase the hypotensive activities of Tetrahydropalmatine. Investigational Thalidomide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Thalidomide. Approved, Investigational, Withdrawn Theodrenaline Nitrendipine may increase the hypotensive activities of Theodrenaline. Investigational Thiamylal The metabolism of Nitrendipine can be increased when combined with Thiamylal. Approved, Vet Approved Thiopental The metabolism of Nitrendipine can be increased when combined with Thiopental. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Thioridazine. Withdrawn Thymol The risk or severity of adverse effects can be increased when Thymol is combined with Nitrendipine. Approved Tibolone Nitrendipine may increase the hypotensive activities of Tibolone. Approved Ticagrelor The serum concentration of Ticagrelor can be increased when it is combined with Nitrendipine. Approved Ticlopidine The metabolism of Nitrendipine can be decreased when combined with Ticlopidine. Approved Ticrynafen Nitrendipine may increase the hypotensive activities of Ticrynafen. Withdrawn Timolol The serum concentration of Timolol can be increased when it is combined with Nitrendipine. Approved Tioconazole The risk or severity of adverse effects can be increased when Tioconazole is combined with Nitrendipine. Approved Tizanidine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Tizanidine. Approved Tocilizumab The serum concentration of Nitrendipine can be decreased when it is combined with Tocilizumab. Approved Tolazoline Tolazoline may increase the hypotensive activities of Nitrendipine. Approved, Vet Approved Tolcapone The risk or severity of adverse effects can be increased when Nitrendipine is combined with Tolcapone. Approved, Withdrawn Tolciclate The risk or severity of adverse effects can be increased when Tolciclate is combined with Nitrendipine. Experimental Tolnaftate The risk or severity of adverse effects can be increased when Tolnaftate is combined with Nitrendipine. Approved, Vet Approved Tolonidine Nitrendipine may increase the hypotensive activities of Tolonidine. Experimental Toloxatone Toloxatone may increase the hypotensive activities of Nitrendipine. Approved Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Nitrendipine. Approved Topotecan The serum concentration of Topotecan can be increased when it is combined with Nitrendipine. Approved, Investigational Torasemide Torasemide may increase the hypotensive activities of Nitrendipine. Approved Toremifene The serum concentration of Toremifene can be increased when it is combined with Nitrendipine. Approved, Investigational Trandolapril Trandolapril may increase the hypotensive activities of Nitrendipine. Approved Trans-2-Phenylcyclopropylamine Trans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nitrendipine. Experimental Tranylcypromine Tranylcypromine may increase the hypotensive activities of Nitrendipine. Approved Trastuzumab emtansine The serum concentration of Trastuzumab emtansine can be increased when it is combined with Nitrendipine. Approved Travoprost Travoprost may increase the hypotensive activities of Nitrendipine. Approved Treprostinil Treprostinil may increase the hypotensive activities of Nitrendipine. Approved, Investigational Tretinoin The risk or severity of adverse effects can be increased when Nitrendipine is combined with Tretinoin. Approved, Investigational, Nutraceutical Triamterene The risk or severity of adverse effects can be increased when Nitrendipine is combined with Triamterene. Approved Trichlormethiazide Trichlormethiazide may increase the hypotensive activities of Nitrendipine. Approved, Vet Approved Trimazosin Trimazosin may increase the hypotensive activities of Nitrendipine. Experimental Trimethaphan Trimethaphan may increase the hypotensive activities of Nitrendipine. Approved Trimetrexate The risk or severity of adverse effects can be increased when Trimetrexate is combined with Nitrendipine. Approved, Investigational Tylosin The metabolism of Nitrendipine can be decreased when combined with Tylosin. Vet Approved Ubidecarenone The serum concentration of Ubidecarenone can be increased when it is combined with Nitrendipine. Experimental Udenafil Udenafil may increase the antihypertensive activities of Nitrendipine. Approved, Investigational Ulipristal The serum concentration of Ulipristal can be increased when it is combined with Nitrendipine. Approved Umeclidinium The serum concentration of Umeclidinium can be increased when it is combined with Nitrendipine. Approved Unoprostone Nitrendipine may increase the hypotensive activities of Unoprostone. Approved Urapidil Urapidil may increase the hypotensive activities of Nitrendipine. Investigational Ursodeoxycholic acid Ursodeoxycholic acid can cause a decrease in the absorption of Nitrendipine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Valsartan Valsartan may increase the hypotensive activities of Nitrendipine. Approved, Investigational Vardenafil Vardenafil may increase the antihypertensive activities of Nitrendipine. Approved Vecuronium The serum concentration of Vecuronium can be increased when it is combined with Nitrendipine. Approved Velpatasvir The serum concentration of Velpatasvir can be increased when it is combined with Nitrendipine. Approved Venetoclax The serum concentration of Venetoclax can be increased when it is combined with Nitrendipine. Approved Venlafaxine The metabolism of Nitrendipine can be decreased when combined with Venlafaxine. Approved Verapamil The metabolism of Nitrendipine can be decreased when combined with Verapamil. Approved Vinblastine The serum concentration of Vinblastine can be increased when it is combined with Nitrendipine. Approved Vincamine Nitrendipine may increase the hypotensive activities of Vincamine. Experimental Vincristine The serum concentration of Vincristine can be increased when it is combined with Nitrendipine. Approved, Investigational Vinpocetine Nitrendipine may increase the hypotensive activities of Vinpocetine. Investigational Vismodegib The serum concentration of Vismodegib can be increased when it is combined with Nitrendipine. Approved Voriconazole The metabolism of Nitrendipine can be decreased when combined with Voriconazole. Approved, Investigational Voxilaprevir The serum concentration of Voxilaprevir can be increased when it is combined with Nitrendipine. Approved Xipamide Nitrendipine may increase the hypotensive activities of Xipamide. Experimental Xylometazoline Nitrendipine may increase the hypotensive activities of Xylometazoline. Approved Yohimbine Yohimbine may decrease the antihypertensive activities of Nitrendipine. Approved, Vet Approved Zidovudine The serum concentration of Zidovudine can be increased when it is combined with Nitrendipine. Approved Ziprasidone The metabolism of Nitrendipine can be decreased when combined with Ziprasidone. Approved Zofenopril Nitrendipine may increase the hypotensive activities of Zofenopril. Experimental - Food Interactions
- Not Available
References
- Synthesis Reference
Wolfgang Schmidt, Bernhard Streuff, Manfred Winter, "Preparation of solid medicament formulation containing nitrendipine." U.S. Patent US4724141, issued April, 1980.
US4724141- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB15187
- KEGG Drug
- D00629
- KEGG Compound
- C07713
- PubChem Compound
- 4507
- PubChem Substance
- 46508817
- ChemSpider
- 4351
- BindingDB
- 50012016
- ChEBI
- 7582
- ChEMBL
- CHEMBL475534
- Therapeutic Targets Database
- DAP001263
- PharmGKB
- PA146096020
- IUPHAR
- 2334
- Guide to Pharmacology
- GtP Drug Page
- Wikipedia
- Nitrendipine
- ATC Codes
- C08CA08 — Nitrendipine
- C08CA — Dihydropyridine derivatives
- C08C — SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
- C08 — CALCIUM CHANNEL BLOCKERS
- C — CARDIOVASCULAR SYSTEM
- AHFS Codes
- Not Available
- PDB Entries
- Not Available
- FDA label
- Not Available
- MSDS
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Unknown Status Treatment Hypertensive 1 4 Withdrawn Treatment Chronic Kidney Disease (CKD) / Hypertensive 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 156-160 °C Not Available water solubility Insoluble Not Available logP 2.88 MASUMATO,K ET AL. (1995) Caco2 permeability -4.77 ADME Research, USCD - Predicted Properties
Property Value Source Water Solubility 0.0142 mg/mL ALOGPS logP 3.21 ALOGPS logP 2.17 ChemAxon logS -4.4 ALOGPS pKa (Strongest Basic) 5.43 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 110.45 Å2 ChemAxon Rotatable Bond Count 7 ChemAxon Refractivity 96.91 m3·mol-1 ChemAxon Polarizability 36.25 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9536 Blood Brain Barrier - 0.9549 Caco-2 permeable + 0.7853 P-glycoprotein substrate Substrate 0.5265 P-glycoprotein inhibitor I Inhibitor 0.8564 P-glycoprotein inhibitor II Inhibitor 0.8313 Renal organic cation transporter Non-inhibitor 0.8984 CYP450 2C9 substrate Non-substrate 0.8212 CYP450 2D6 substrate Non-substrate 0.8931 CYP450 3A4 substrate Substrate 0.7266 CYP450 1A2 substrate Inhibitor 0.9107 CYP450 2C9 inhibitor Inhibitor 0.8949 CYP450 2D6 inhibitor Non-inhibitor 0.9231 CYP450 2C19 inhibitor Inhibitor 0.8993 CYP450 3A4 inhibitor Inhibitor 0.8037 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.9247 Ames test Non AMES toxic 0.7334 Carcinogenicity Non-carcinogens 0.5186 Biodegradation Not ready biodegradable 0.9581 Rat acute toxicity 2.3810 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8131 hERG inhibition (predictor II) Non-inhibitor 0.9094
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-QFT , negative LC-MS/MS splash10-0ab9-2539000000-3d9a9111a145f234fc24 MS/MS Spectrum - , positive LC-MS/MS splash10-016r-0159000000-7b0ccf9fb639868092f0 LC-MS/MS Spectrum - LC-ESI-QFT , positive LC-MS/MS splash10-016r-0159000000-4e10a6643ba97ab23a0f
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Pyridines and derivatives
- Sub Class
- Hydropyridines
- Direct Parent
- Dihydropyridinecarboxylic acids and derivatives
- Alternative Parents
- Nitrobenzenes / Nitroaromatic compounds / Dicarboxylic acids and derivatives / Vinylogous amides / Enoate esters / Methyl esters / Amino acids and derivatives / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Enamines show 6 more
- Substituents
- Dihydropyridinecarboxylic acid derivative / Nitrobenzene / Nitroaromatic compound / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Benzenoid / Methyl ester / Enoate ester / Alpha,beta-unsaturated carboxylic ester / Vinylogous amide show 23 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- C-nitro compound, ethyl ester, diester, dihydropyridine (CHEBI:7582)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Voltage-gated calcium channel activity
- Specific Function
- Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
- Gene Name
- CACNA1C
- Uniprot ID
- Q13936
- Uniprot Name
- Voltage-dependent L-type calcium channel subunit alpha-1C
- Molecular Weight
- 248974.1 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Voltage-gated calcium channel activity
- Specific Function
- The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-...
- Gene Name
- CACNA2D1
- Uniprot ID
- P54289
- Uniprot Name
- Voltage-dependent calcium channel subunit alpha-2/delta-1
- Molecular Weight
- 124566.93 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Voltage-gated calcium channel activity
- Specific Function
- The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
- Gene Name
- CACNB2
- Uniprot ID
- Q08289
- Uniprot Name
- Voltage-dependent L-type calcium channel subunit beta-2
- Molecular Weight
- 73579.925 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Voltage-gated calcium channel activity
- Specific Function
- This protein is a subunit of the dihydropyridine (DHP) sensitive calcium channel. Plays a role in excitation-contraction coupling. The skeletal muscle DHP-sensitive Ca(2+) channel may function only...
- Gene Name
- CACNG1
- Uniprot ID
- Q06432
- Uniprot Name
- Voltage-dependent calcium channel gamma-1 subunit
- Molecular Weight
- 25028.105 Da
References
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Voltage-gated calcium channel activity involved sa node cell action potential
- Specific Function
- Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
- Gene Name
- CACNA1D
- Uniprot ID
- Q01668
- Uniprot Name
- Voltage-dependent L-type calcium channel subunit alpha-1D
- Molecular Weight
- 245138.75 Da
References
- Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Voltage-gated calcium channel activity
- Specific Function
- Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
- Gene Name
- CACNA1S
- Uniprot ID
- Q13698
- Uniprot Name
- Voltage-dependent L-type calcium channel subunit alpha-1S
- Molecular Weight
- 212348.1 Da
References
- Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Voltage-gated calcium channel activity
- Specific Function
- The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-t...
- Gene Name
- CACNA2D2
- Uniprot ID
- Q9NY47
- Uniprot Name
- Voltage-dependent calcium channel subunit alpha-2/delta-2
- Molecular Weight
- 129816.095 Da
References
- Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Scaffold protein binding
- Specific Function
- Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
- Gene Name
- CACNA1H
- Uniprot ID
- O95180
- Uniprot Name
- Voltage-dependent T-type calcium channel subunit alpha-1H
- Molecular Weight
- 259160.2 Da
References
- Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
References
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A7
- Uniprot ID
- P24462
- Uniprot Name
- Cytochrome P450 3A7
- Molecular Weight
- 57525.03 Da
References
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674]
- Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K: Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci. 2002 Aug;16(3):159-65. [PubMed:12128170]
Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:51